Absci (NASDAQ:ABSI) Shares Down 9.8% – Time to Sell?

Absci Corporation (NASDAQ:ABSI)’s stock price traded down 9.8% during mid-day trading on Tuesday. The stock traded as low as $9.87 and last traded at $9.7450. Approximately 2,290,562 shares changed hands during mid-day trading, a decline of 47% from the average session volume of 4,299,767 shares. The stock had previously closed at $10.80.

Key Headlines Impacting Absci

Here are a few of the latest headlines about ABSI:

• Positive Sentiment: Absci said its Phase 2 HEADLINE trial of ABS-201 for pattern hair loss remains on track, with 13-week proof-of-concept data expected in December 2026 and 26-week results expected in early 2027. The data could be an important clinical catalyst. Absci reports business updates and third-quarter results
• Positive Sentiment: The company reported $173.7 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2028. It also plans to start a Phase 2 ABS-201 trial for endometriosis in mid-2027. Absci reports third-quarter loss as ABS-201 trial advances
• Negative Sentiment: Third-quarter revenue was $0.3 million, below analyst expectations of $0.66 million and down from $0.4 million a year earlier. Net loss widened to $33.3 million from $28.7 million, while research and development spending increased. Although reported EPS of $0.19 loss matched one consensus estimate, another estimate cited by Zacks indicated a modest miss. Absci reports third-quarter earnings results

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. BTIG Research set a $15.00 price objective on Absci and gave the company a “buy” rating in a research note on Tuesday, September 8th. Jefferies Financial Group started coverage on Absci in a research report on Thursday, October 29th. They set a “buy” rating and a $14.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Absci in a research note on Wednesday, September 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Absci in a research note on Tuesday, October 20th. Finally, Lifesci Capital assumed coverage on Absci in a research report on Wednesday, September 9th. They issued an “outperform” rating on the stock. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Absci Stock Down 4.1%

The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -12.12 and a beta of 2.22. The business’s fifty day moving average is $9.65 and its two-hundred day moving average is $6.75.

Absci (NASDAQ:ABSI) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.66 million. Absci had a negative return on equity of 61.71% and a negative net margin of 7,756.38%. Research analysts forecast that Absci Corporation will post -0.76 EPS for the current year.

Institutional Trading of Absci

Several institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Absci during the second quarter worth $141,112,000. Siren L.L.C. bought a new position in Absci during the first quarter worth about $5,400,000. Parkman Healthcare Partners LLC bought a new position in Absci during the second quarter worth about $10,366,000. Bank of America Corp DE bought a new position in Absci during the second quarter worth about $6,560,000. Finally, Artia Global Partners LP acquired a new position in shares of Absci during the 2nd quarter worth about $5,383,000. Institutional investors own 52.05% of the company’s stock.

Absci Company Profile

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.